Phenotypic and Genetic Analyses of Korean Patients with Familial Hypercholesterolemia: Results from the KFH Registry 2020.
Diagnosis
Far East
Hyperlipoproteinemia type II
Mutation
Journal
Journal of atherosclerosis and thrombosis
ISSN: 1880-3873
Titre abrégé: J Atheroscler Thromb
Pays: Japan
ID NLM: 9506298
Informations de publication
Date de publication:
01 Aug 2022
01 Aug 2022
Historique:
pubmed:
31
8
2021
medline:
3
8
2022
entrez:
30
8
2021
Statut:
ppublish
Résumé
Familial hypercholesterolemia (FH) is currently a worldwide health issue. Understanding the characteristics of patients is important for proper diagnosis and treatment. This study aimed to analyze the phenotypic and genetic features, including threshold cholesterol levels, of Korean patients with FH. A total of 296 patients enrolled in the Korean FH registry were included, according to the following criteria: low-density lipoprotein-cholesterol (LDL-C) >190 mg/dL with tendon xanthoma or family history compatible with FH, or LDL-C >225 mg/dL. DNA sequences of three FH-associated genes were obtained using whole-exome or target exome sequencing. Threshold cholesterol levels for differentiating patients with FH/pathogenic variant (PV) carriers and predictors of PVs were identified. Of the 296 patients, 104 had PVs and showed more obvious clinical findings, including higher cholesterol levels. PV rates ranged from 30% to 64% when patients were categorized by possible or definite type according to the Simon Broome criteria. Frequent PV types included missense variants and copy number variations (CNVs), while the most frequent location of PVs was p.P685L in LDLR. The threshold LDL-C levels for patient differentiation and PV prediction were 177 and 225 mg/dL, respectively. Younger age, tendon xanthoma, and higher LDL-C levels were identified as independent predictors of PVs, while traditional cardiovascular risk factors were predictors of coronary artery disease. Korean patients with FH had variable PV rates depending on diagnostic criteria and distinctive PV locations. The reported threshold LDL-C levels pave the way for efficient patient care in this population.
Identifiants
pubmed: 34456200
doi: 10.5551/jat.63062
pmc: PMC9371750
doi:
Substances chimiques
Cholesterol, LDL
0
Receptors, LDL
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1176-1187Références
Atherosclerosis. 2018 Oct;277:308-313
pubmed: 30270064
PLoS One. 2015 May 11;10(5):e0126706
pubmed: 25962062
J Lipid Atheroscler. 2019 Sep;8(2):78-131
pubmed: 32821702
J Am Coll Cardiol. 2018 Aug 7;72(6):662-680
pubmed: 30071997
Eur Heart J. 2017 Feb 21;38(8):565-573
pubmed: 27044878
Clin Genet. 2010 Jun;77(6):572-80
pubmed: 20236128
J Clin Lipidol. 2020 May - Jun;14(3):346-351.e9
pubmed: 32331935
Clin Genet. 2020 Nov;98(5):457-467
pubmed: 32770674
J Lipid Atheroscler. 2019 Sep;8(2):183-191
pubmed: 32821708
Atherosclerosis. 2015 Nov;243(1):53-8
pubmed: 26343872
Eur Heart J. 2017 May 21;38(20):1573-1579
pubmed: 28159968
Atherosclerosis. 2019 Nov;290:140-205
pubmed: 31591002
Sci Rep. 2020 Nov 9;10(1):19336
pubmed: 33168860
Eur J Prev Cardiol. 2020 Jul 27;:2047487320942996
pubmed: 32718233
J Atheroscler Thromb. 2018 Aug 1;25(8):751-770
pubmed: 29877295
Atherosclerosis. 2020 Sep;308:48-49
pubmed: 32736795
J Atheroscler Thromb. 2020 Dec 1;27(12):1288-1298
pubmed: 32759540
Atherosclerosis. 2018 Oct;277:419-424
pubmed: 30270080
Eur Heart J. 2016 May 01;37(17):1384-94
pubmed: 26908947
Atherosclerosis. 2013 Jul;229(1):161-8
pubmed: 23669246
Circ J. 2019 Aug 23;83(9):1917-1924
pubmed: 31327807
J Lipid Res. 2017 Nov;58(11):2202-2209
pubmed: 28874442
Curr Opin Lipidol. 2019 Apr;30(2):63-70
pubmed: 30664016
J Atheroscler Thromb. 2005;12(1):35-40
pubmed: 15725694
J Atheroscler Thromb. 2017 Mar 1;24(3):189-207
pubmed: 28179607